Kura Oncology Inc. (KURA) Rating Lowered to Sell at Zacks Investment Research
Kura Oncology Inc. (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Separately, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a research report on Tuesday, June 21st.
Kura Oncology (NASDAQ:KURA) opened at 7.16 on Tuesday. Kura Oncology has a 52-week low of $2.50 and a 52-week high of $25.00. The firm’s market capitalization is $134.20 million. The firm’s 50-day moving average is $5.53 and its 200-day moving average is $3.97.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, analysts anticipate that Kura Oncology will post ($1.58) earnings per share for the current year.
A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC bought a new stake in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned approximately 0.34% of Kura Oncology as of its most recent filing with the SEC. Institutional investors own 43.63% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.